biochemistry

A team of global scientists found an antibody-based therapeutic that they hope will stop the next rodent-borne hantavirus outbreak in its tracks.

Antibiotic resistance is on the rise and scientists are on the lookout for new therapeutics for treating human pathogens. One promising new venture repurposes antimalarial drugs to treat patients with chronic lung diseases such as cystic fibrosis.

Membraneless droplet like organelles known as condensates are changing the way some scientists approach drug discovery.

Researchers no longer think that proteins blindly swim through the cytoplasm hoping to bump into one another. Instead, they intentionally aggregate with other biomolecules, forming membrane free, transient organelles called condensates.

The company plans to develop more specialized, antibody-based GPCR drugs to treat a myriad of diseases. They recruited a leader in overseeing successful clinical trials to get the job done.

COVID-19 has gotten a little better at infecting cells and dodging antibodies with each set of mutations in new variants. Omicron is the best at dodging antibodies, but its modified structure sacrificed virulence for antibody resistance.